Translating and updating for generic medicines

In the highly regulated pharmaceutical landscape, the translation and maintenance of product information for generic medicines is far more than a linguistic exercise. It is a regulatory obligation that demands precision, consistency and adherence to the reference medicinal product (‘originator’). For pharmaceutical companies offering generics across multiple markets, ensuring that the product information remains aligned with the reference product is a continuous and often complex process. This is where life science translation expertise plays a pivotal role.

Generic medicines are authorised based on their bioequivalence to an already approved reference medicinal product. Identical in dosage and intended use, they become available once the patent on the original brand-name drug expires. As such, the product information files (Summary of Product Characteristics (SPC), Patient Information Leaflet (PIL) and label) must closely reflect those of the originator product.

Regulatory authorities such as the European Medicines Agency (EMA) and national agencies require that:

• The SPC content of a generic mirrors the reference product text, with only limited, justified differences, including the correction of errors or changes in terminological preferences amongst national agencies.
• The PIL is consistent with the SPC, e.g. in terms of the adverse reactions, and maintains readability and patient-friendliness. Whilst the SPC often features technical jargon for medical experts, the PIL must use easy-to-understand language to ensure correct product usage.
• Ongoing updates (variations) to the reference product are tracked and mirrored in generic product information. The reasons for these updates can be broken down into three categories:  1) Chemistry, Manufacturing and Controls (CMC); 2) clinical, safety and efficacy updates such as a newly discovered adverse reaction; and 3) administrative updates such as a change in manufacturing site details or ATC code.

Deviations from the reference product text, whether intentional or accidental, can result in regulatory findings, delays in approvals, or even compliance risks. This is because the reference product document has already earned regulatory body’s seal of approval. Yet translators must understand which changes are mandatory and which are product-specific. All the while, it’s crucial to adhere to national templates and QRD (Quality Review of Documents) conventions, ensuring the end result reflects both the central reference and local regulatory expectations.

SPCs, PILs and labels are living documents. Safety updates, pharmacovigilance data, and regulatory decisions frequently trigger variations. For companies offering generic products, this translates into a need for continuously monitoring the reference product and promptly implementing updates across all languages. A lack of synchronisation can result in inconsistencies and compliance risks.

Translation providers must therefore operate as strategic partners, supporting version control and change tracking and offering rapid turnaround times on multilingual updates. Close collaboration between regulatory affairs teams and reliable translation providers allows for efficient roll-out across markets and minimises bottlenecks in submission procedures.

Generic product information requires translators who are well acquainted with regulatory frameworks (EMA, MHRA, etc.), QRD templates, and handling variations and lifecycle updates. On top of this comes knowledge of the relevant specialist terminology and where to find the latest terminology recommendations. In this way, life science translation providers support regulatory compliance, helping ensure that generic product information remains accurate, compliant, and aligned with the reference product at all times.

In the world of generic medicines, translating and updating SPCs and PILs is a high-stakes task where precision and consistency are non-negotiable. Alignment with the reference product forms the cornerstone of patient safety and product integrity. Partnering with a life science translation provider who understands these complexities is essential to maintaining compliance and ensuring seamless market access across regions.

First Edition Translations collaborates with CROs, pharmaceutical manufacturers, university hospitals, and MedComms agencies across the globe. Within our ISO-certified framework, our multilingual project managers work alongside our specialised life science translators and linguistic validation consultants to ensure optimal quality across the board. We’ve been in the business since the dawn of the 80s – and for good reason. Whatever the size of your project and whatever languages you require, we are happy to discuss your needs under enquiries@firstedit.co.uk